Lpath Ranks Eighth Fastest Growing Biotechnology Company and 60th Overall Among N. America's Fastest Growing Companies in Deloitte's 2012 Technology Fast 500

Mon Dec 3, 2012 8:31am EST

* Reuters is not responsible for the content in this press release.

  SAN DIEGO, CA, Dec 03 (Marketwire) -- 
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive
lipid-targeted therapeutics, ranked eighth among biotechnology and
pharmaceutical companies and 60th overall on the 2012 Technology Fast
500(TM), Deloitte's ranking of 500 of the fastest growing life sciences,
technology, media, telecommunications and clean technology companies in
North America.

    "The 2012 Deloitte Technology Fast 500 winners have demonstrated
remarkable innovation and spectacular growth," said Eric Openshaw, vice
chairman and U.S. technology, media and telecommunications leader,
Deloitte LLP. "Some of the most exciting and useful developments of the
future are being created by the companies on this list. We congratulate
Lpath and all of the winning companies on this impressive achievement."

    Scott Pancoast, Lpath's president and chief executive officer, commented:
"These rankings are a validation of our unique antibody drug-discovery
engine and our dominating intellectual property. Our platform produces
novel therapeutics that address significant market opportunities where
there is a clear clinical need. The rankings also reflect our ability to
attract financial and strategic partners such as Pfizer, J&J, Biogen
Idec, and Merck-Serono, as well as the NIH and the Department of Defense."

    Utilizing its ImmuneY2(TM) drug-discovery engine, Lpath has developed
several first-in-class therapeutic antibodies. Each of these antibodies
are designed to target bioactive signaling lipids, such as S1P
(sphingosine-1-phosphate) and LPA (lysophosphatidic acid), that are
involved in the proliferation and spread of neuropathic pain, wet AMD,
inflammatory and auto-immune disorders, cancer, and many other diseases.

    Lpath is currently moving forward in mid-stage clinical trials with two
anti-S1P antibody formulations. iSONEP(TM) is currently being evaluated
in a Phase 2 clinical trial, called Nexus, which is evaluating the
anti-S1P antibody's safety and efficacy in wet-AMD patients; ASONEP(TM)
will soon be evaluated in a Phase 2a clinical trial in patients with
renal cell carcinoma.

    Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that
provides Pfizer an exclusive option for a worldwide license to develop
and commercialize iSONEP. 

    For additional detail on the Technology Fast 500(TM), including selection
and qualifying criteria, visit www.fast500.com.

    About Lpath
 San Diego-based Lpath, Inc., a therapeutic antibody company,
is the category leader in lipid-targeted therapeutics, an emerging field
of medicine that targets bioactive signaling lipids for treating a wide
range of human disease. Lpath's ImmuneY2(TM) drug-discovery engine has
the unique ability to generate therapeutic antibodies that bind to and
inhibit bioactive lipids that contribute to disease. The company has
developed three drug candidates: iSONEP(TM) is currently in a Phase 2
clinical trial for wet AMD; ASONEP(TM) will soon begin a Phase 2a
clinical trial in Renal Cell Carcinoma patients; and Lpathomab is a
preclinical drug candidate that holds promise in neuropathic pain,
neurotrauma, and other diseases. For more information, visit

    About Forward-Looking Statements
 The Company cautions you that the
statements included in this press release that are not a description of
historical facts are forward-looking statements. These include statements
regarding: the protection against competition afforded by issued patents;
the eventual commercial viability of the Company's drug programs; and the
Company's ability to complete additional discovery and development
activities for drug candidates utilizing its proprietary ImmuneY2 drug
discovery process. Actual results may differ materially from those set
forth in this press release due to the risks and uncertainties inherent
in the Company's business, including, without limitation: the outcome of
the final analyses of the data from the Phase 1 clinical trial may vary
from the Company's initial conclusions; the results of any future
clinical trials for iSONEP or ASONEP may not be favorable and the Company
may never receive regulatory approval for iSONEP or ASONEP or any of its
drug candidates; and the Company's may not be able to secure the funds
necessary to support its clinical trial and product development plans.
More detailed information about the Company and the risk factors that may
affect the realization of forward-looking statements is set forth in the
Company's filings with the Securities and Exchange Commission, including
its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q
filed with the SEC. Such documents may be read free of charge on the
SEC's web site at www.sec.gov. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and the Company undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof. This caution is made under the safe
harbor provisions of Section 21E of the Private Securities Litigation
Reform Act of 1995.


Lpath, Inc.
Scott R. Pancoast
President & CEO
(858) 926-3200 

Lpath Investor Relations
Liolios Group, Inc. 
(949) 574-3860
Ron Both: ron@liolios.com 
Geoffrey Plank: geoffrey@liolios.com 

Copyright 2012, Marketwire, All rights reserved.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.